Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO

BACKGROUND: A pre-specified meta-analysis of individual patient data from the 52-week METREX and METREO trials, which investigated mepolizumab for chronic obstructive pulmonary disease (COPD) in patients with blood eosinophil counts ≥150 cells/µL (screening) or ≥300 cells/µL (prior year) and frequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavord, Ian D, Chapman, Kenneth R, Bafadhel, Mona, Sciurba, Frank C, Bradford, Eric S, Schweiker Harris, Stephanie, Mayer, Bhabita, Rubin, David B, Yancey, Steven W, Paggiaro, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215850/
https://www.ncbi.nlm.nih.gov/pubmed/34163157
http://dx.doi.org/10.2147/COPD.S294333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215850/
https://www.ncbi.nlm.nih.gov/pubmed/34163157
http://dx.doi.org/10.2147/COPD.S294333

Ejemplares similares